Pictet Asset Management Holding SA Has $47.50 Million Position in DexCom, Inc. $DXCM

Pictet Asset Management Holding SA trimmed its holdings in DexCom, Inc. (NASDAQ:DXCM) by 1.6% during the first quarter, Holdings Channel reports. The institutional investor owned 756,328 shares of the medical device company’s stock after selling 12,448 shares during the quarter. Pictet Asset Management Holding SA’s holdings in DexCom were worth $47,497,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in DXCM. Reflection Asset Management acquired a new stake in shares of DexCom in the 4th quarter worth about $25,000. CVA Family Office LLC boosted its stake in DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 147 shares during the last quarter. MCF Advisors LLC bought a new stake in DexCom during the 4th quarter worth approximately $32,000. ORG Partners LLC raised its stake in shares of DexCom by 124.3% in the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after purchasing an additional 281 shares during the last quarter. Finally, DV Equities LLC purchased a new stake in shares of DexCom in the fourth quarter worth approximately $36,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Raymond James Financial reiterated a “strong-buy” rating and set a $91.00 price target on shares of DexCom in a report on Monday, June 8th. Mizuho set a $85.00 price target on shares of DexCom and gave the company an “outperform” rating in a research report on Tuesday, June 9th. Deutsche Bank Aktiengesellschaft began coverage on shares of DexCom in a report on Tuesday, June 23rd. They set a “buy” rating and a $86.00 price target on the stock. Canaccord Genuity Group set a $82.00 target price on DexCom and gave the company a “buy” rating in a report on Monday, May 18th. Finally, BTIG Research reiterated a “buy” rating and set a $85.00 price target on shares of DexCom in a report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $84.88.

DexCom Trading Down 0.2%

Shares of DXCM stock opened at $69.98 on Tuesday. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The firm has a market cap of $27.00 billion, a P/E ratio of 29.91, a PEG ratio of 1.16 and a beta of 1.45. The company has a 50 day moving average of $67.83 and a 200-day moving average of $68.12. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The business had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the prior year, the business earned $0.32 earnings per share. DexCom’s revenue for the quarter was up 15.0% on a year-over-year basis. Sell-side analysts anticipate that DexCom, Inc. will post 2.57 earnings per share for the current year.

Insider Transactions at DexCom

In related news, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the sale, the director directly owned 25,007 shares in the company, valued at approximately $1,500,670.07. The trade was a 3.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,911 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $74.13, for a total transaction of $364,052.43. Following the sale, the executive vice president directly owned 95,450 shares in the company, valued at approximately $7,075,708.50. This trade represents a 4.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 46,694 shares of company stock valued at $3,343,977. 0.28% of the stock is currently owned by insiders.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.